Picard Medical / SynCardia COO to Deliver Keynote at Venture Café Phoenix During Arizona Tech Week

Rhea-AI Summary

Picard Medical (NYSE American: PMI) announced that SynCardia COO Matt Schuster will deliver a keynote at Venture Café Phoenix during Arizona Tech Week on April 9, 2026, 6:20–6:40 p.m. at the Phoenix Bioscience Core CEI Main Stage.

The keynote will highlight next‑generation fully implantable total artificial heart technology, efforts to expand access for women with advanced heart failure, and recent clinical experience at leading transplant centers including UCSF.

News Market Reaction – PMI

-9.43%

7 alerts

-9.43% Session close to close

-5.0% Trough in 3 hr 12 min

$75.19M Market Cap

0.9x Rel. Volume

In the Apr 2 session, PMI declined 9.43%, reflecting a notable negative market reaction. Argus tracked a trough of -5.0% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -9.4% in the session following this news. A negative reaction despite this visibilit...

Analysis

The stock moved -9.4% in the session following this news. A negative reaction despite this visibility-focused announcement fits prior episodes where positive clinical or promotional updates were followed by pullbacks, including moves of -4.65% and -10.24%. The keynote adds awareness but does not change reported financials or disclosed clinical outcomes. Past behavior suggests that even constructive news around the SynCardia platform has not always supported sustained strength after initial headlines.

Key Figures

Keynote date: April 9, 2026 Keynote duration: 20 minutes Program duration: 2.5 hours

3 metrics

Keynote date April 9, 2026 Venture Café Phoenix keynote

Keynote duration 20 minutes 6:20 p.m. to 6:40 p.m. session

Program duration 2.5 hours 4:30 p.m. to 7:00 p.m. broader program

Historical Context

5 past events · Latest: Mar 25 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 25	Full-year earnings	Positive	+3.0%	Reported 2025 revenue growth and stronger cash position after public listing.
Mar 20	Conference presentation	Positive	+2.7%	Announced preclinical Emperor Total Artificial Heart data at ACC.26 meeting.
Mar 19	Clinical milestone	Positive	-3.5%	Highlighted 119-day SynCardia support before successful transplant at UCSF.
Mar 17	Long-term support case	Positive	-10.2%	Reported 1,636-day SynCardia support leading to transplant in 29-year-old patient.
Mar 13	Media feature	Positive	-4.7%	Announced BTV on FOX Business segment on SynCardia artificial heart.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent product and clinical visibility news has often seen mixed or negative price reactions, while earnings and data presentations have produced modest gains.

Recent Company History

Over the past weeks, Picard Medical has reported 2025 financials showing revenue of $4.94M and improved operating performance, which was followed by a 3.03% gain. Multiple news items have highlighted the SynCardia Total Artificial Heart: new UCSF bridge-to-transplant milestones, a four-year support case, and broadcast exposure on FOX Business, with price moves ranging from -10.24% to +2.68%. Today’s Arizona Tech Week keynote continues this pattern of clinical and visibility-focused outreach rather than new financial data.

Key Terms

total artificial heart, advanced heart failure, mechanical circulatory support, fda

4 terms

total artificial heart medical

"maker of the world’s first total artificial heart approved by both the U.S."

A total artificial heart is a surgically implanted mechanical device that replaces the heart’s two main pumping chambers and takes over circulation, acting like a continuous pump that keeps blood moving through the body. Investors care because it is a high-cost, high-stakes medical product whose commercial success depends on clinical trial results, regulatory approvals, hospital adoption, reimbursement rules and long-term patient outcomes — factors that drive revenue potential and risk.

advanced heart failure medical

"women with advanced heart failure – TUCSON, Ariz., April 02, 2026 -- Picard"

Advanced heart failure is a severe, chronic condition in which the heart can no longer pump enough blood to meet the body's needs despite standard treatments, causing frequent symptoms, hospital stays, and the need for specialized therapies. For investors, it signals a clear market for high-cost interventions—drugs, medical devices, hospitals and transplant or mechanical support technologies—so clinical results, approvals, and reimbursement decisions can materially affect revenue, costs and company valuations; think of it as a failing engine that requires costly, often long-term repairs or replacement.

mechanical circulatory support medical

"remain underrepresented in mechanical circulatory support. The broader program"

Mechanical circulatory support are medical devices that help or take over the heart’s job of moving blood around the body, ranging from temporary external pumps to implanted pumps that assist one or both sides of the heart. For investors, these devices matter because their use drives sales, regulatory scrutiny, reimbursement decisions and long‑term healthcare costs; think of them as a backup engine for a failing heart whose adoption and outcomes influence a company’s market opportunity and risk profile.

fda regulatory

"artificial heart approved by both the U.S. FDA and Health Canada, today"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

– Keynote to highlight innovation in artificial heart technology and expanding access for women with advanced heart failure –

TUCSON, Ariz., April 02, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Chief Operating Officer Matt Schuster will deliver a keynote address at Venture Café Phoenix during Arizona Tech Week, an event that brings together founders, investors, and innovators to showcase Arizona’s growing technology ecosystem.

Information for Keynote Address at Venture Café Phoenix

Location: Phoenix Bioscience Core at the Center for Entrepreneurial Innovation (CEI) Main Stage located 850 N 5th Street, Phoenix, AZ.

Date and time: Thursday April 9, 2026, from 6:20 p.m. to 6:40 p.m.

Register at:
https://community.venturecafephoenix.org/events/6875508c-69d8-4945-b5ce-6a540e006b7b.

Mr. Schuster’s keynote will focus on the evolving role of artificial heart technology in addressing critical gaps in the treatment of advanced heart failure, particularly among underserved patient populations. His presentation will address how next generation, fully implantable total artificial heart systems may expand access to life sustaining therapy, improve mobility and quality of life, and broaden eligibility for treatment, including for women, who remain underrepresented in mechanical circulatory support.

The broader program will run from 4:30 p.m. to 7:00 p.m. and will include the FemTech AZ Pitch Competition and an International Innovation Mixer focused on women’s health innovation and cross border collaboration.

“Picard Medical’s / SynCardia’s participation in AZ Tech Week reflects the Company’s commitment to advancing next-generation medical technologies through innovation and clinical collaboration and events like Venture Café Phoenix provide an important platform to connect innovation with real world patient needs,” said Matt Schuster, Chief Operating Officer of Picard Medical. “As we continue to advance artificial heart technology, we remain focused on expanding access to therapy and addressing longstanding gaps in care, including those that affect women with advanced heart failure.”

The presentation will also highlight recent clinical experience with the SynCardia Total Artificial Heart at leading transplant centers, including the University of California, San Francisco, where cardiac surgeon Dr. Amy Fiedler and her team have recently implanted the SynCardia Total Artificial Heart in multiple patients as part of advanced heart failure care.

About Arizona Tech Week

Arizona Tech Week is a statewide innovation conference that convenes founders, investors, researchers, and industry leaders through a series of events held across Arizona. The program highlights emerging technologies, entrepreneurship, and collaboration across sectors including life sciences, healthcare, artificial intelligence, and advanced manufacturing. Events such as the Venture Café Phoenix Thursday Gathering provide a platform for innovators and companies to showcase new technologies, exchange ideas, and strengthen Arizona’s rapidly growing innovation ecosystem.

About the Phoenix Bioscience Core and Venture Café Phoenix

The Phoenix Bioscience Core (PBC) is a 30-acre life sciences innovation district located in downtown Phoenix that brings together leading academic institutions including Arizona State University, Northern Arizona University, and the University of Arizona, alongside research organizations such as the Translational Genomics Research Institute, part of City of Hope, and the International Genomics Consortium. The district also collaborates closely with major healthcare systems including Banner Health, Phoenix Children’s, Dignity Health, HonorHealth, the Phoenix VA, and Valleywise Health, creating a hub for biomedical research, clinical innovation, and technology development.

Venture Café Phoenix hosts its flagship “Thursday Gathering” at 850 N 5th Street, bringing together entrepreneurs, investors, researchers, and industry leaders each week to exchange ideas and build connections. Held every Thursday from 4:30 pm to 7:00 pm, the gathering attracts more than 150 participants and features breakout sessions, mentor hours, demonstrations, and community programming designed to foster collaboration and strengthen Arizona’s innovation ecosystem.

About Picard Medical and SynCardia

Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona-based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.

For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.

Contact:

Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com

Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com

General/Media
Brittany Lanza
blanza@syncardia.com

FAQ

What will Picard Medical (PMI) COO Matt Schuster discuss at Venture Café Phoenix on April 9, 2026?

He will discuss next‑generation fully implantable total artificial heart systems and access for underserved patients. According to the company, the talk will emphasize expanding eligibility, improving mobility and quality of life, and addressing underrepresentation of women in mechanical circulatory support.

When and where is Picard Medical (PMI) presenting during Arizona Tech Week?

Picard Medical will present on April 9, 2026 from 6:20 p.m. to 6:40 p.m. at the Phoenix Bioscience Core CEI Main Stage. According to the company, the keynote is part of Venture Café Phoenix's evening program during Arizona Tech Week.

How does the PMI keynote address plan to address treatment gaps for women with advanced heart failure?

The keynote will focus on broadening eligibility and access for women through device design and clinical strategies. According to the company, next‑generation total artificial heart systems may improve inclusion and address longstanding underrepresentation in mechanical circulatory support.

Will Picard Medical (PMI) reference clinical results or center experience during the April 9 keynote?

Yes. The presentation will highlight recent clinical experience with the SynCardia Total Artificial Heart at leading transplant centers. According to the company, examples include multiple implants performed by teams at the University of California, San Francisco.

How can investors or attendees register for Matt Schuster's keynote at Venture Café Phoenix?

Interested attendees can register through the Venture Café Phoenix event page for the April 9 session. According to the company, the keynote is open to founders, investors, and innovators attending Arizona Tech Week and related programming.

Does Picard Medical (PMI) link the keynote to broader company strategy or collaboration?

The company frames the keynote as part of its commitment to innovation and clinical collaboration in artificial heart technology. According to the company, events like Venture Café Phoenix connect technology development with real‑world patient needs and partners.